← Browse by Condition
Medical Condition
pulmonary arterial hypertension
Total Trials
5
Recruiting Now
5
Trial Phases
Phase 3
Hypertension remains the most common treatable cardiovascular risk factor globally, yet blood pressure control rates remain suboptimal despite multiple effective drug classes. Clinical trials now investigate novel mechanisms including aldosterone synthase inhibitors, renal denervation devices, and RNA-based therapies targeting angiotensinogen to achieve durable pressure reduction with minimal pill burden.
Active research includes zilebesiran (RNA interference targeting angiotensinogen), baxdrostat (aldosterone synthase inhibitor), ultrasound renal denervation (Symplicity HTN-4), and resistant hypertension approaches combining SGLT2 inhibitors with MRA spironolactone. Ambulatory blood pressure monitoring is increasingly used as the primary endpoint instead of clinic readings.
Frequently Asked Questions — pulmonary arterial hypertension Clinical Trials
How many clinical trials are currently recruiting for pulmonary arterial hypertension?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for pulmonary arterial hypertension, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pulmonary arterial hypertension?
pulmonary arterial hypertension research spans Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pulmonary arterial hypertension clinical trial?
Eligibility criteria for pulmonary arterial hypertension trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07217522
Recruiting
Rutgers University Study of the Genetics of Pulmonary Hypertension
Enrollment
10,000 pts
Location
United States
Sponsor
Rutgers, The State University ...
NCT07481981 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Enrollment
344 pts
Location
United States
Sponsor
Insmed Incorporated
NCT04278404
Recruiting
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Enrollment
5,000 pts
Location
United States, Canad...
Sponsor
Duke University
NCT06804122
Recruiting
Exercise-based Rehabilitation in Patients With Pulmonary Arterial Hypertension
Enrollment
20 pts
Location
Finland
Sponsor
Tampere Heart Hospital
NCT07365332 Phase 3
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Enrollment
486 pts
Location
United States
Sponsor
Inhibikase Therapeutics
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology